FDA Pulls Keytruda from Two Clinical Trials after Deaths

September 1, 2017

(UPI) – The FDA has placed a full clinical hold on two clinical trials combining the cancer drug Keytruda with other therapies after an excess of deaths was reported. The agency announced on Thursday that two clinical trials of Keytruda, or pembrolizumab, combined with two other therapies have been halted after the trial sponsor, Merck, stopped enrolling patients into the trials and reported its concerns in June to the FDA.